

James M Hoffman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3652978/publications.pdf>

Version: 2024-02-01

87
papers

4,995
citations

117625

34
h-index

95266

68
g-index

87
all docs

87
docs citations

87
times ranked

4942
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacists Leading the Way to Precision Medicine: Updates to the Core Pharmacist Competencies in Genomics. American Journal of Pharmaceutical Education, 2022, 86, 8634.	2.1	21
2	Why do subcutaneous ports get stuck? A case-control study. Journal of Pediatric Surgery, 2022, 57, 229-233.	1.6	3
3	ASHP Statement on the Pharmacist's Role in Clinical Pharmacogenomics. American Journal of Health-System Pharmacy, 2022, 79, 704-707.	1.0	37
4	Advancing pharmacogenomics into practice. American Journal of Health-System Pharmacy, 2022, 79, 603-604.	1.0	1
5	National trends in prescription drug expenditures and projections for 2022. American Journal of Health-System Pharmacy, 2022, 79, 1158-1172.	1.0	22
6	An adaptive, asymptomatic SARS-CoV-2 workforce screening program providing real-time, actionable monitoring of the COVID-19 pandemic. PLoS ONE, 2022, 17, e0268237.	2.5	3
7	Advancing Pharmacogenomics from Single-Gene to Preemptive Testing. Annual Review of Genomics and Human Genetics, 2022, 23, 449-473.	6.2	15
8	A nucleic acid amplification test-based strategy does not help inform return to work for healthcare workers with COVID-19. Influenza and Other Respiratory Viruses, 2022, 16, 851-853.	3.4	1
9	The Effects of the Second Victim Phenomenon on Work-Related Outcomes: Connecting Self-Reported Caregiver Distress to Turnover Intentions and Absenteeism. Journal of Patient Safety, 2021, 17, 195-199.	1.7	87
10	Expanding evidence leads to new pharmacogenomics payer coverage. Genetics in Medicine, 2021, 23, 830-832.	2.4	49
11	ASHP Foundation Pharmacy Forecast 2021: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2021, 78, 472-497.	1.0	12
12	National trends in prescription drug expenditures and projections for 2021. American Journal of Health-System Pharmacy, 2021, 78, 1294-1308.	1.0	32
13	Approaches to assessing the provider experience with clinical pharmacogenomic information: a scoping review. Genetics in Medicine, 2021, 23, 1589-1603.	2.4	3
14	Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA - Journal of the American Medical Association, 2021, 325, 2500.	7.4	83
15	Associations of job demands and patient safety event involvement on burnout among a multidisciplinary group of pediatric hematology/oncology clinicians. Pediatric Blood and Cancer, 2021, 68, e29214.	1.5	5
16	Never Enough Time: Mixed Methods Study Identifies Drivers of Temporal Demand That Contribute to Burnout Among Physicians Who Care for Pediatric Hematology-Oncology Patients. JCO Oncology Practice, 2021, 17, e958-e971.	2.9	4
17	Validation of the Second Victim Experience and Support Tool-Revised in the Neonatal Intensive Care Unit. Journal of Patient Safety, 2021, 17, 531-540.	1.7	22
18	The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. Clinical Pharmacology and Therapeutics, 2020, 107, 171-175.	4.7	207

#	ARTICLE	IF	CITATIONS
19	ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2020, 77, 84-112.	1.0	29
20	Improving Patient Handoffs and Transitions through Adaptation and Implementation of I-PASS Across Multiple Handoff Settings. Pediatric Quality & Safety, 2020, 5, e323.	0.8	32
21	National trends in prescription drug expenditures and projections for 2020. American Journal of Health-System Pharmacy, 2020, 77, 1213-1230.	1.0	34
22	Biomedical Data Science and Informatics Challenges to Implementing Pharmacogenomics with Electronic Health Records. Annual Review of Biomedical Data Science, 2020, 3, 289-314.	6.5	10
23	Preemptively Precise: Returning and Updating Pharmacogenetic Test Results to Realize the Benefits of Preemptive Testing. Clinical Pharmacology and Therapeutics, 2019, 106, 942-944.	4.7	17
24	Priorities for Pediatric Patient Safety Research. Pediatrics, 2019, 143, .	2.1	33
25	Accelerating Improvement in Children's Healthcare Through Quality Improvement Collaboratives: a Synthesis of Recent Efforts. Current Treatment Options in Pediatrics, 2019, 5, 111-130.	0.6	11
26	National trends in prescription drug expenditures and projections for 2019. American Journal of Health-System Pharmacy, 2019, 76, 1105-1121.	1.0	29
27	Optimizing Drug-Drug Interaction Alerts Using a Multidimensional Approach. Pediatrics, 2019, 143, .	2.1	14
28	Developing Evidence for New Patient Safety Bundles Through Multihospital Collaboration. Journal of Patient Safety, 2019, Publish Ahead of Print, e1576-e1584.	1.7	8
29	ASHP Foundation Pharmacy Forecast 2019: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2019, 76, 71-100.	1.0	14
30	Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genetics in Medicine, 2019, 21, 1224-1232.	2.4	57
31	ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2018, 75, 23-54.	1.0	19
32	Using EHR Data to Detect Prescribing Errors in Rapidly Discontinued Medication Orders. Applied Clinical Informatics, 2018, 09, 082-088.	1.7	5
33	Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics, 2018, 19, 847-860.	1.3	53
34	The Second Victim Experience and Support Tool: Validation of an Organizational Resource for Assessing Second Victim Effects and the Quality of Support Resources. Journal of Patient Safety, 2017, 13, 93-102.	1.7	159
35	Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. American Journal of Health-System Pharmacy, 2017, 74, 409-415.	1.0	14
36	ASHP Foundation Pharmacy Forecast 2017: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2017, 74, 27-53.	1.0	10

#	ARTICLE	IF	CITATIONS
37	Pharmacogenomics competencies in pharmacy practice: A blueprint for change. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 120-125.	1.5	58
38	Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). <i>Genetics in Medicine</i> , 2017, 19, 215-223.	2.4	410
39	Leveraging precision medicine to mitigate medication-safety challenges. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 2031-2032.	1.0	0
40	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1977-1985.	1.0	79
41	Patient Safety Culture and the Second Victim Phenomenon: Connecting Culture to Staff Distress in Nurses. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2016, 42, 377-AP2.	0.7	89
42	Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 796-801.	4.4	83
43	Integrating pharmacogenomics into electronic health records with clinical decision support. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1967-1976.	1.0	118
44	Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. <i>Pediatrics</i> , 2016, 138, .	2.1	71
45	The genomic CDS sandbox: An assessment among domain experts. <i>Journal of Biomedical Informatics</i> , 2016, 60, 84-94.	4.3	4
46	Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, e138-e141.	4.4	30
47	ASHP Guidelines on Preventing Medication Errors with Chemotherapy and Biotherapy. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, e6-e35.	1.0	72
48	Preventing chemotherapy errors: Updating guidelines to meet new challenges. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 668-669.	1.0	2
49	Accuracy of annual prescription drug expenditure forecasts in<i>AJHP</i>. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1642-1648.	1.0	3
50	Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 89-106.	9.4	442
51	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. <i>Current Drug Metabolism</i> , 2014, 15, 209-217.	1.2	341
52	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 499-500.	4.7	123
53	Development and use of active clinical decision support for preemptive pharmacogenomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, e93-e99.	4.4	186
54	Economic Evaluations of Clinical Pharmacy Services: 2006â€“2010. <i>Pharmacotherapy</i> , 2014, 34, 771-793.	2.6	148

#	ARTICLE	IF	CITATIONS
55	National trends in prescription drug expenditures and projections for 2014. American Journal of Health-System Pharmacy, 2014, 71, 482-499.	1.0	62
56	Adverse Drug Event Detection in Pediatric Oncology and Hematology Patients: Using Medication Triggers to Identify Patient Harm in a Specialized Pediatric Patient Population. Journal of Pediatrics, 2014, 165, 447-452.e4.	1.8	30
57	PG4KDS: A model for the clinical implementation of preemptive pharmacogenetics. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 45-55.	1.6	221
58	Biosimilars: Implications for health-system pharmacists. American Journal of Health-System Pharmacy, 2013, 70, 2004-2017.	1.0	54
59	Posaconazole Therapeutic Drug Monitoring in Pediatric Patients and Young Adults with Cancer. Annals of Pharmacotherapy, 2013, 47, 976-983.	1.9	50
60	National survey on the effect of oncology drug shortages on cancer care. American Journal of Health-System Pharmacy, 2013, 70, 609-617.	1.0	90
61	The safety of cefepime and ceftazidime in pediatric oncology patients. Pediatric Blood and Cancer, 2013, 60, 806-809.	1.5	7
62	Projecting future drug expenditures in U.S. nonfederal hospitals and clinics—2013. American Journal of Health-System Pharmacy, 2013, 70, 525-539.	1.0	19
63	Implications of the FDA Draft Guidance on Biosimilars for Clinicians: What We Know and Don't Know. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 368-372.	4.9	5
64	Projecting future drug expenditures—2012. American Journal of Health-System Pharmacy, 2012, 69, 405-421.	1.0	59
65	A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clinical Pharmacology and Therapeutics, 2012, 92, 563-566.	4.7	94
66	Safe and Successful Implementation of CPOE for Chemotherapy at a Children's Cancer Center. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-36-S-50.	4.9	26
67	NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-22.	4.9	118
68	Development and implementation of a pharmacist-managed clinical pharmacogenetics service. American Journal of Health-System Pharmacy, 2011, 68, 143-150.	1.0	128
69	Projecting future drug expenditures—2011. American Journal of Health-System Pharmacy, 2011, 68, 921-932.	1.0	34
70	NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-7-S-27.	4.9	18
71	Efficacy and Safety of Cefepime in Pediatric Patients: A Systematic Review and Meta-Analysis. Journal of Pediatrics, 2010, 157, 490-495.e1.	1.8	17
72	Projecting future drug expenditures—2010. American Journal of Health-System Pharmacy, 2010, 67, 919-928.	1.0	19

#	ARTICLE	IF	CITATIONS
73	Risk evaluation and mitigation strategies: Challenges and opportunities for health-system pharmacists. American Journal of Health-System Pharmacy, 2010, 67, 1547-1554.	1.0	10
74	Intravenous Zanamivir for Oseltamivir-Resistant 2009 H1N1 Influenza. New England Journal of Medicine, 2010, 362, 88-89.	27.0	128
75	Transparent and reproducible reports of economic evaluations of clinical pharmacy services: A goal for the future?. American Journal of Health-System Pharmacy, 2009, 66, 442-443.	1.0	3
76	Projecting future drug expendituresâ€”2009. American Journal of Health-System Pharmacy, 2009, 66, 237-257.	1.0	36
77	Economic Evaluations of Clinical Pharmacy Services: 2001â€”2005. Pharmacotherapy, 2009, 29, 128-128.	2.6	84
78	Projecting future drug expendituresâ€”2008. American Journal of Health-System Pharmacy, 2008, 65, 234-253.	1.0	32
79	Projecting future drug expendituresâ€”2007. American Journal of Health-System Pharmacy, 2007, 64, 298-314.	1.0	27
80	Projecting future drug expendituresâ€”2006. American Journal of Health-System Pharmacy, 2006, 63, 123-138.	1.0	26
81	Projecting future drug expendituresâ€”2005. American Journal of Health-System Pharmacy, 2005, 62, 149-167.	1.0	32
82	Pharmacy residency training in academic medical centers. American Journal of Health-System Pharmacy, 2004, 61, 2528-2533.	1.0	18
83	Patent expiration for lansoprazole. American Journal of Health-System Pharmacy, 2004, 61, 2253-2253.	1.0	0
84	Projecting future drug expendituresâ€”2004. American Journal of Health-System Pharmacy, 2004, 61, 145-158.	1.0	26
85	Medication Errors Caused by Confusion of Drug Names. Drug Safety, 2003, 26, 445-452.	3.2	83
86	Projecting future drug expendituresâ€”2003. American Journal of Health-System Pharmacy, 2003, 60, 137-149.	1.0	25
87	Quality improvement knowledge in pediatric hematology/oncology physicians: A need for improved education. Pediatric Blood and Cancer, 0, , .	1.5	0